| Judy B Kilpatrick, LMFT | |
|
228 Main St E, Ahoskie, NC 27910-3418 | |
| (252) 209-0388 | |
| (252) 209-0488 |
| Full Name | Judy B Kilpatrick |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 228 Main St E, Ahoskie, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366786345 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 1478 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Judy B Kilpatrick, LMFT 228 Main St E, Ahoskie, NC 27910-3418 Ph: (252) 209-0388 | Judy B Kilpatrick, LMFT 228 Main St E, Ahoskie, NC 27910-3418 Ph: (252) 209-0388 |
News Archive
Childhood obesity rates have nearly tripled in the previous 30 years and researchers are asking the important question of how this epidemic will impact the future health of these obese children and public health in general. A University of Colorado Cancer Center article recently published in the journal Gerontology shows that even in cases in which obese children later lose weight, the health effects of childhood obesity may be long-lasting and profound.
Health Canada is informing health care professionals and Canadians of recent changes to heparin manufacturing standards in the United States that will result in a decrease in the potency of certain heparin products by about 10 per cent.
Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).
Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received notification from the European Patent Office that its patent application entitled "Device and Method for Administering Therapeutic Agents" has been approved and a patent will be granted.
Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease.
› Verified 1 days ago